Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its technological innovations and diversification plans regarding its product portfolio. The optimism, led by a solid third-quarter...
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #2 (Buy)...
HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of 78 cents in third-quarter fiscal 2025, surpassing the Zacks Consensus Estimate by 9.86%. The bottom line improved 30% on a year-over-year...
Accuray Incorporated ARAY is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in the first quarter...
DENTSPLY SIRONA XRAY is well-poised for growth due to its robust product portfolio and continued focus on research and development. However, forex remains a concern.Shares of this Zacks Rank #3 (Hold)...
Inari Medical, Inc. NARI is well poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency...
Penumbra, Inc. PEN is likely to grow in the coming quarters, backed by the strength exhibited in the Thrombectomy business. The company’s robust portfolio expansion looks promising. However, the impact...